Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
LAUSANNE, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of ...
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


